RX-0047 / Opus Genetics - LARVOL DELTA

Programmed delivery of cyclopeptide RA-V and antisense oligonucleotides for combination therapy on hypoxic tumors and for therapeutic self-monitoring. (PubMed, Biomater Sci) - "This work should synergistically enhance the therapeutic effects of the treatment by successfully down-regulating HIF-1α expression against tumor hypoxia during the RA-V-induced apoptotic process. More importantly, the RA/RX Liposome can be precisely applied for therapeutic self-monitoring with the light-up fluorescence of the caspase-8 probe."

Combination therapy • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Azoreductase-responsive Metal-organic Frameworks-based Nanodrug for Enhanced Cancer Therapy via Breaking Hypoxia-induced Chemoresistance. (PubMed, ACS Appl Mater Interfaces) - "As far as we known, this is the first attempt to construct AMOFs-based nanodrug with hypoxic harvesting behaviors. This proof-of-concept research both provides a simple strategy to the construction of hypoxic-responsive mechanized AMOFs, and offers a unique on-command drug delivery platform which can effectively break hypoxia-induced chemoresistance."

Journal